From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

There is more than one reason why DS Smith held a fascinating presentation yesterday

By Chris Bailey of Financial Orbit | Friday 16 April 2021


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


First I see that GlaxoSmithKline (GSK) shares were nicely firm yesterday.  As I noted here back in mid-February I could see an opportunity to buy the shares…which I did later on that month.  Yesterday’s move was driven by an article – planted in the FT – which noted that “Hedge fund Elliott builds up multibillion-pound stake in GSK…Activist group’s investment comes as UK drugmaker’s performance lags rivals”. 

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Tuesday »

G4M

Gea4Music – time to call a bottom?

 

Clown

Which PR genius wrote this?

 

HAT

H&T Group – now again a Buy

Time left: 11:43:11